NASH +

CORONARY STENTS

OVERVIEW

Coronary Stent NASH+ Everolimus drug-eluting is designed to increase luminal diameter of coronary vessels in patients with ischemic heart disease symptoms, including patients with acute myocardial infarction and patients with comorbid diabetes mellitus, caused by de novo local lesions of native coronary arteries.

CLINICAL STUDIES

SPECIFICATIONS

Ultra-thin stent strut thickness (65 µm) reduces the risk of late stent thrombosis
Ultra-low crossing profile (~1.0 mm) of the stent provides improved flexibility and deliverability
Enhanced radial strength of the stent guarantees reliable support of the vessel wall and reduces recoil risk (<5%), ensuring a stable result after implantation
Thin bioresorbable polymer coating 3 µm thick reduces the risk of vascular inflammation
The polymer coating application technology preserves the integrity of the polymer coating after stent expansion and ensures controlled systemic drug release
Guidewire Compatibility: max 0.014’’
Guide catheter compatibility: 5F
NP: 8 ATM
RBP: 16 ATM
Radiopaque Markers: Pt-Ir (2 pcs)
Balloon Material: Nylon/Pebax

RESOURCES

Registration Certificate

NASH+ Brochure